Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
Q5146 Trastuzumab-strf (hercessi) Hercessi 10mg Immunotherapy Monoclonal Antibody HER2 No 2025 Jan 1, 2025 In Use
J9034 Bendamustine Bendeka 1 mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2008 Jan 1, 2017 In Use
J0594 Busulfan Busulfex 1 mg Chemotherapy Alkylating Agent Alkylsulfonate No 1999 Jan 1, 2007 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
J9275 Zanidatamab-hrii ZIIHERA 2mg Immunotherapy Bispecific Antibody HER2 No 2024 May 13, 2025 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
Q5101 Filgrastim Neupogen, Zarxio 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jul 1, 2015 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
J0207 Amifostine Ethyol 500 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan 1, 1998 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J9306 Pertuzumab Perjeta 1 mg Immunotherapy Monoclonal Antibody HER2 No 2012 Jan 1, 2014 In Use
J9310 Rituximab Rituxan 100 mg Immunotherapy Monoclonal Antibody CD20 No 1997 Jan 1, 1999 In Use
J1729 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 10 mg Hormonal Therapy Progestin No 2011 Jan 1, 2018 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No Apr 1, 2002 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
J9190 Fluorouracil Adrucil 500 mg Chemotherapy Antimetabolite Pyrimidine Analog No 1962 Jan 1, 1984 In Use
J9214 Interferon Alfa-2b Intron A 1 million units Immunotherapy Cytokine Interferon No 1986 Jan 1, 1993 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
J9262 Omacetaxine Synribo 0.01 mg Chemotherapy Plant Alkaloid BCR-ABL No 2012 Jan 1, 2014 In Use
S0182 Procarbazine Matulane 50 mg Chemotherapy Alkylating Agent Benzamide Yes 1969 Jan 1, 2002 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.